Aim To analyse the clinical features, laboratory data and foetal-maternal outcomes, and
follow them up on a cohort of 1000 women with obstetric antiphospholipid syndrome …

Abstract Purpose of Review The antiphospholipid syndrome (APS) is characterized by the
development of thrombotic events and pregnancy morbidity in the presence of …

In antiphospholipid syndrome (APS), the risk of clinical manifestations increases with higher
titers of antiphospholipid antibodies (aPL). Despite the adoption of aPL titers in the …

Long-term vitamin K antagonist (VKA) anticoagulation is the cornerstone of the management
of subjects with thrombotic antiphospholipid syndrome (APS). Recent investigations have …

Objective This article aims to analyse the rate of antiphospholipid antibodies (aPL)
negativisation in patients with antiphospholipid syndrome (APS), and to evaluate potential …

Objective The withdrawal of oral anticoagulation (OAC) in patients with SLE and secondary
aPL syndrome (SAPS) who become seronegative has not been clearly investigated to date …

Background/purpose Pediatric antiphospholipid syndrome (APS) is a thromboinflammatory
disease characterized by the presence of circulating antiphospholipid antibodies and either …

Introduction: Some patients with positive antiphospholipid antibodies (aPL) have not been
included in randomized clinical trials or observational registries and, therefore, information …

Progress continues to be made in pursuit of improving the lives of individuals afflicted with
APS. The most important future directions would seem to involve leveraging modern …

The current mainstay of treatment in patients with thrombotic antiphospholipid syndrome
(APS) is long-term anticoagulation, mainly with Vitamin K antagonist agents. Some recently …